4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Leiomyosarcoma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 266 ongoing clinical trials involving Leiomyosarcoma
Of the 266 trials,80 trials are in Phase II
Furthermore, 71 trials are in Phase I

Number of ongoing Clinical Trials (for drugs) involving Leiomyosarcoma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Leiomyosarcoma, an Oncology condition. The largest number of ongoing clinical trials for Leiomyosarcoma is conducted in North America. Europe and Asia-Pacific are among some of the other prominent regions engaged in Leiomyosarcoma-related drug trials.

Memorial Sloan Kettering Cancer Center: The leading ongoing Leiomyosarcoma related clinical trial sponsor

Memorial Sloan Kettering Cancer Center is the top sponsor for Leiomyosarcoma-related ongoing clinical trials.

National Cancer Institute US, Sun Yat-sen University, Fox Chase Cancer Center, Philogen SpA, and Pharma Mar SA are among other notable clinical trial sponsors involved in Leiomyosarcoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Leiomyosarcoma

Trabectedin (Yondelis), Dacarbazine (Dazine) and Ifosfamide (Evolox / Famifoda) are the key marketed drug involving Leiomyosarcoma.

Trabectedin (Yondelis) is an anti-tumor agent of marine origin discovered in the Caribbean tunicate, ecteinascidia turbinata. It functions via the DNA Synthesis inhibitor’s mechanism of action. It is formulated as a lyophilized powder for solution for injection for intravenous route of administration. Yondelis is indicated for the treatment of adult patients with advanced soft tissue sarcoma, after the failure of anthracyclines and ifosfamide, or those who are unsuited to receive these agents. Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer. Trabectedin was first approved in 2007 and is marketed globally including the US, the UK, Australia, France, Germany, and Japan by Johnson & Johnson.

Dacarbazine (Dazine) is an imidazole derivative, acts as antineoplastic agent. It functions via DNA synthesis inhibitor’s mechanism of action It is formulated as a powder for solution for intravenous route of administration. Dazine is indicated in the treatment of metastatic malignant melanoma, Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents, neuroblastoma, soft tissue sarcoma including leiamyosarcoma. Dacarbazine is marketed in India by Zuvius Lifesciences Pvt Ltd.